You are here
Formulary Kit for LOKELMA
INDICATION AND LIMITATION OF USE
- ► LOKELMA is indicated for the treatment of hyperkalemia in adults
- ► LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action
FORMULARY KIT COMPONENTS
IMPORTANT SAFETY INFORMATION FOR LOKELMA 10 g FOR ORAL SUSPENSION
WARNINGS AND PRECAUTIONS:
- Gastrointestinal Adverse Events in Patients with Motility Disorders: Avoid LOKELMA in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders. LOKELMA has not been studied in patients with these conditions and it may be ineffective and may worsen gastrointestinal conditions
- Edema: Each 5 g dose of LOKELMA contains approximately 400 mg of sodium. In clinical trials of LOKELMA, edema was generally mild to moderate in severity and was more commonly seen in patients treated with 15 g once daily. Monitor for signs of edema, particularly in patients who should restrict their sodium intake or are prone to fluid overload (eg., heart failure or renal disease). Advise patients to adjust dietary sodium, if appropriate. Increase the dose of diuretics as needed
ADVERSE REACTIONS: The most common adverse reaction with LOKELMA was mild to moderate edema. In placebo-controlled trials up to 28 days, edema was reported in 4.4%, 5.9%, 16.1% of patients treated with 5 g, 10 g and 15 g of LOKELMA once daily, respectively vs 2.4% of patients receiving placebo.
DRUG INTERACTIONS: LOKELMA can transiently increase gastric pH. In general, oral medications with pH-dependent solubility should be administered at least 2 hours before or 2 hours after LOKELMA. Spacing is not needed if it has been determined the concomitant medication does not exhibit pH-dependent solubility.
Please read full Prescribing Information.
You may report side effects related to AstraZeneca products by clicking here.
LOKELMA is a trademark of the AstraZeneca group of companies.
©2018 AstraZeneca. All rights reserved.
US-23728 Last Updated 9/18